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Abstract
Background: The aim of this study was to review the available literature and define
clinical practice guidelines for the use of laser and other light therapies for the prevention
and treatment of oral mucositis.
Methods: A systematic review was conducted by the Mucositis Study Group of the
Multinational Association of Supportive Care in Cancer / International Society for Oral
Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer
treatment setting, was assigned an evidence level. Based on the evidence level, one of the
following three guideline determinations was possible: Recommendation, Suggestion, No
guideline possible.
Results: A recommendation was made for low level laser (wavelength at 650 nm, power
of 40 mW, and each cm2 treated with the required time to a tissue energy dose of
2J//cm2) for the prevention of oral mucositis in adult patients receiving hematopoietic
stem cell transplantation conditioned with high-dose chemotherapy with or without total
body irradiation. A suggestion was made for low level laser (wavelength around 632.8
nm, the power of 10-60 mW, and each cm2 treated with the required time to a tissue
energy dose of 2j/cm2) for the prevention of oral mucositis in patients undergoing
radiotherapy for head and neck cancer. No guideline was possible for other light sources
such as infra-red LED and broad band visible light therapy, due to insufficient evidence.

Conclusions Best evidence available supports the use of GaAlAs at 650 nm wavelength
at low intensity of 40 mW and each cm2 treated with the required time to a tissue energy
dose of 2J/cm2 for the prevention of oral mucositis in HSCT patients. Additional lasers
and other light sources were reported to be effective in similar wavelengths range and
intensities. Well-designed research is needed to evaluate the oral mucositis prevention
and treatment efficacy of other laser wavelengths and light therapy in other cancer
treatment settings.

Keywords: oral mucositis, stomatitis, laser therapy, LLLT, LED, oral complications of
cancer therapy, mucositis prevention, mucositis treatment
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Introduction
This manuscript is part of a collaborative effort of the Multinational Association
of Supportive Care in Cancer (MASCC) mucositis study group to update the existing
guidelines for the prevention and treatment of oral mucositis in cancer patients. The
original and last update of the guidelines in 2004 and 2007 respectively 1,2 reviewed the
various therapies for mucositis, including the use of low level laser therapy (LLLT). 3
LLLT is based on the interaction of light at low energy density, a few J/cm2, with
cells and tissues without the generation of thermal effects. This type of therapy is
believed to promote photochemical, photophysical and photobiological effects in cells
and tissues, without causing temperature rise above 98o F. It is believed that the
biomodulation effect over cells and tissues occurs due to the absorption of the laser light
by endogenous photoreceptors.4 In 1989, a review of several in vitro studies 5 revealed
that primary phothoactivated receptors are components of the cellular respiratory chain.
The activation of these receptors could lead to the stimulation or inhibition of the cellular
metabolism, depending on the energy dose of light. Low energy doses could regulate the
production of reactive oxygen species (ROS). It is known that the radiation wavelength
can be beneficial to cells and tissues, 4 but there is uncertainty on how this happens.
Visible light can lead to photochemical changes in the photoreceptors in the
mitochondria, altering cell metabolism and producing a transduction effect in other cell
components (biomodulation effect). 5 Others suggest that this effect is due to photo
physical changes on the Ca++ channels in the cell membrane .6
At the time of the last MASCC/ISOO mucositis guidelines review,3 studies testing
laser therapy were few. Variable protocols for preventing and treating mucositis, the large
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variation in the wavelength used, the technique used to deliver laser to tissues, and the
use of diverse mucositis-grading tools did not allow for conclusive results making it
impossible to standardize a particular protocol. Although the results were encouraging,
no recommendation for the use of the LLLT was possible. As part of a comprehensive
update of the MASCC/ISOO clinical practice guidelines for mucositis, the aim of this
project was to systematically review the available literature and define evidence-based
clinical practice guidelines for the use of laser and other light therapy devices for the
prevention and treatment of oral mucositis.
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Methods
The methods used in this systematic review are described in detail in Bowen et al.
[[ref in this issue]] and Elad et al. [[ref in this issue]]. Briefly, a literature search for
relevant papers indexed before 31st December 2010 was conducted using
OVID/MEDLINE, with papers selected for review based on defined inclusion and
exclusion criteria.
Selected papers were reviewed by two independent expert reviewers and data was
extracted using a standard electronic form. Studies were scored for their Level of
Evidence based on Somerfield criteria 7 and flaws were listed according to Hadorn
criteria. 8 A well-designed study was defined as a study with no major flaws per the
Hadorn criteria. 8
Findings from the reviewed studies were integrated into guidelines based on the
overall Level of Evidence for laser and other light therapy agents. Guidelines were
classified into 3 types: recommendation, suggestion, and no guideline possible.
Guidelines were separated based on 1) the aim of the intervention (prevention or
treatment of mucositis); 2) the treatment modality (radiotherapy, chemotherapy, chemoradiotherapy, or high dose conditioning therapy for hematopoietic stem cell transplant),
and 3) the route of administration of the intervention, when applicable.
The list of intervention keywords used for the literature search of this section
included oral mucositis or stomatitis AND lasers, laser, LLLT, low level laser therapy,
light therapy, phototherapy, low-level laser, LED, light-emitting diode, diode, visible
light, He-Ne, InGaAlP, GaAlAs, InGaAs, CO2, and infra-red.
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Results
The literature search identified a total of 692 papers from which a total of 24
clinical trials were included for final review. 9-32 The literature review process can be
seen in Figure 1.

HSCT induced oral mucositis
A recommendation was possible for laser therapy in the wavelength around 650
nm, the intensity of 40 mW, and each cm2 treated with the required time to a tissue
energy dose of 2J/cm2 for the prevention of mucositis in HSCT. This guideline is based
on the combination of one well-designed randomized clinical trial with no major flaws 11
together with a series of studies reporting positive results with laser in a similar range of
wavelength which were classified as lower level of evidence.
The pivotal trial evaluated the efficacy of two different low level Gallium
Aluminum Arsenide (GaAlAs) diode lasers, 650nm and 780nm wavelengths in the
prevention of oral mucositis in Hematopoietic Stem Cell Transplantation (HSCT) patients
conditioned with chemotherapy or chemoradiotherapy. 11 Patients with clinically normal
oral mucosa received intra-oral laser irradiation in several areas of the mucosa, with
energy densities of 2J/cm2. Because of the preventive nature of the study, laser treatment
began on the first day of the conditioning and continued through day +2 post HSCT. It
was observed that the severity of oral mucositis score in patients treated with the 650nm
laser were reduced, compared with placebo, and the 780nm laser groups (p=0.06). Of
importance is the fact that patients in the 650 nm group statistically significantly likely
received total body irradiation (TBI) thus a more aggressive therapy protocol. An
8

adjusted statistical test for TBI showed that the difference in mucositis severity on day 11
post HSCT was statistically significant (p=0.03). Laser therapy was well-tolerated and no
adverse events developed.

In contrast to the above mentioned guideline, no guideline was possible for laser
as a treatment of oral mucositis in HSCT patients. A single study with mixed cancer
population 17 was insufficient to allow for a stronger guideline.
Two non-laser light-therapy devices were reported in the literature for the prevention of
oral mucositis in HSCT patient population: LED and broad band visible light therapy.
18,19

Since it is unclear at present whether these modalities have the same mechanism as

laser therapy, each was referred separately. As to LED, there are accumulating data
showing that there is no difference in the interaction of a laser and a LED with the human
tissue. 33-37 These studies showed positive effects in prevention and treatment of oral
mucositis but represent initial investigations of new light technologies and with the
available information no guideline was possible.

Radiotherapy induced oral mucositis
A suggestion was possible for the laser therapy in the prevention of oral mucositis
in patients undergoing radiotherapy for head and neck cancer. This guideline is based on
3 studies showing positive results with laser therapy in the wavelength of 632 nm. 21-23
However, all three studies had major and minor flaws which did not allow for a
recommendation.
Radio-chemotherapy induced oral mucositis
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No guideline was possible for laser therapy in the prevention and or treatment of
oral mucositis in patients treated with combined protocol of radio-chemotherapy for head
and neck cancer. Studies were inconsistent in demonstrating effectiveness of laser
therapy. 24-26 In addition, major flaws in study design reduced the overall level of
evidence to IV.
Chemotherapy induced oral mucositis
No guideline was possible for this category either for prevention of treatment of
mucositis using laser therapy or LED.
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Discussion

This systematic review confirmed that the number of clinical trials assessing the
use of laser and other light therapies in the prevention and control of oral mucositis is
growing. However, it is important to keep in mind that the data presented in this review
results from the use of a variety of low level laser and other light devices that operate in
different wavelengths and are applied to tissues using a variety of protocols. All devices
were within the range considered to be low-level laser (10-200 mW) (Table 1). Laser
application protocols vary greatly and, therefore, conclusions cannot be applied
separately for each of the individual laser devices.
Based on the current scientific information, the panel was able to reach the
following decision: “The panel recommends that, for centers able to support the
necessary technology and training, LLLT be used to prevent oral mucositis, using a low
level laser. Best evidence support the following protocol: 650nm, with the intensity of
40mW and each cm2 treated with the required time to a tissue energy dose of 2J//cm2 to
the oral mucosa in HCT adult population receiving high-dose CT with or without TBI. 11
This represents an improvement from previous guidelines in which the use of laser
therapy was only a suggestion and that new evidence from additional randomized trials
was necessary before a recommendation could be made 1,2, reflecting the growing interest
in the use of these devices in oral mucositis.
The recommendation above is supported by two Cochrane meta-analysis that
evaluated prevention and treatment of oral mucositis with LLLT. The Cochrane
prevention meta-analysis 38 found two studies 13,15 that were considered level III evidence
showing 80% reduction in the incidence of severe mucositis in HSCT. However these
11

studies had major flaws by the Hadorn criteria and therefore, could not be considered for
a recommendation by the panel. In addition, the Cochrane treatment meta-analysis 39
presented two additional studies 17,20 with statistically significant benefits for LLLT in
oral mucositis but had major flaws by Hadorn criteria.
To emphasize the growing body of evidence in favor of LLLT in oral mucositis,
several relevant late-breaking publications have been added to the laser-oral mucositis
literature since the time we completed the literature search in December 2010. A
systematic review with meta-analysis concluded that there is consistent evidence from
small high-quality studies (mostly also included in the present review) that red and
infrared LLLT can partly prevent development of cancer therapy-induced OM. LLLT
significantly reduces pain, severity, and duration of symptoms in patients with OM. 40
Additional data from a trial with near-infrared light-emitting diodes applied extraorally in
children and adults with hematological malignancies and solid tumors treated with HSCT
demonstrated that the technology can significantly reduce patient-reported pain. 41 A
recent randomized study in patients with malignancies treated with HSCT confirmed that
oral mucositis incidence and severity can be reduced with LLLT. 42

Late-breaking studies showed positive outcomes of prevention and treatment of
oral mucositis in head and neck cancer populations being treated with radiation therapy
43

, and in prevention of oral mucositis in head and neck cancer populations being treated

with concurrent chemoradiation confirming that this technology seems to be effective in
controlling the appearance and severity of oral mucositis, its associated pain, and it can
also have beneficial effects on quality of life. 44,45 42
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Indication

Laser
type

Type of
light
therapy

Wavelength
(nm)

Laser setting
(power,
energy, time;
or intensity,,
energy)

Route of
Applicatio
n
(Intra/
Extra-oral)

Treatment
Modality
(HSCT w/wo
TBI, CT, H&N
RT, or mixed)

Patient
populatio
n

Reference
(author, year)

Effectiveness

P

HeNe

Laser

632.8

IO

HSCT w TBI

Adult

Cowen 1997[9]

Y - III

HeNe

Laser

632.8

60mW;
1.5J/cm2, 10
sec
25mW; 1J/cm2,
40 sec

IO

HSCT w/wo TBI

Adult

Barasch
1995[10]

Y - III

GaAlAs

Laser
diode
Laser
diode

650 /
780
660

40/60mW;
2J/cm2, a
10mW
2.5J/cm2, 10
sec

IO

HSCT w/wo TBI

Adult

Y - II

IO

HSCT w/wo TBI

Adult

Schubert
2007[11]
Jaguar
2007[12]

GaAlAs

Laser
diode

780

60mW; 4J/cm2,
time-NS

IO

Mixed: HSCT* &
CT

Pediatric

InGaAIP

Laser
diode

660

40mW;
4/6J/cm2, timeNS

IO

HSCT w/woTBI

InGaAlP

Laser
diode

660

50mW; 4J/cm2,
16.7 sec

IO

InGaAlP
/
GaAlAs

Laser
diode

660 /
780

25mW;
6.3J/cm2, 10
sec

GaAlAs

Laser
diode

830

100mw; 4J/cm2,

GaAlAs

T

b

Overall
level of
evidenc
e

Guideline

Comments

II

Recommendation

He-Ne Laser decreases
severity but not incidence
of OM
He-Ne Laser decreases
severity but not incidence
of OM
Diode 650 nm 2J / cm2
LLLT reduces OM severity
Laser increased time of
OM appearance, reduced
time of pain and morphine
use
No evidence of benefit
from the prophylactic use
of low energy laser in
patients with cancer on
chemotherapy who
received optimal dental
and oral care.
OM measured by WHO
scale was maintained at
grades I and II in 22/30
patients, grade III in 7 and
IV in 1, in HSCT patients
receiving high-dose CT
Preventive use of Laser in
HSCT patients is a
powerful instrument in
reducing the incidence of
OM
LLLT – lower frequency,
progression, and severity
of OM

Y - III

Cruz 2007[13]

N – III

Mixed

Eduardo
2009[14]

Y – IV

HSCT w/woTBI

Adults

Antunes
2007[15]

Y - III

IO

Mixed: HSCT
w/wo TBI & CT

Adults

Khouri
2009[16]

Y - III

IO

Mixed: HSCTd &
CT

Pediatric

Kuhn 2009[17]

Y - III

III

No guideline
possible

encourage pediatric
oncologists to use laser
therapy as first-line option
for children with

P

LED

Light
emitting
diode

670

56mW/cm2
4J/cm2, 71 sec

EO

HSCT w/woTBI

Mixed

Whelan
2002[18]

Y – III

III

No guideline
possible

P

Visible
light

Visible
light

4001200

165200mW/cm2

IO

HSCT d

Adult

Elad 2011[19]

Y - III

III

No guideline
possible

NS

100mW for
“laser”; 50,
250,500mW for
“infra-red”, 2
J/cm2, 33 sec

IO

HSCT w/wo TBI

Adult

GenotKlastersky
2008[20]

Y - III

III

No guideline
possible

60mW; 2J/cm2,
3 sec
10mW;
1.8J/cm2, 3 min
10mW;
1.8J/cm2, b

IO

RT of H&N

Adult

Y - III

III

suggestion

IO

RT of H&N

Adult

EO & IO

RT of H&N

Adult

Bensadoun
1999[21]
Arun Maiya
2006[22]
Arora 2008[23]

T

NS

P

HeNe

Laser

632.8

HeNe

Laser

632.8

HeNe

Laser

632.8

InGaAlP

Laser
diode

685

InGaAlP

Laser
diode

660

P

NS

T

GaAlAs /
InGaAlP

Laser
diode

9-18J/cm2,
45-90 sec

chemotherapy-induced
OM.
Although more studies are
needed, LED therapy
appears useful in the
prevention of OM in
pediatric HSCT patients
Broad band visible light
therapy is safe and
effective in the prevention
of oral mucositis in HSCT
patients.
Therapeutic laser therapy
is beneficial for patients
undergoing HSCT in
delaying the development
of OM grade 3.
in reducing the
He-Ne effective in
preventing RT OM

Y -III

OM healing time reduced
Effective for P & T

Y - III

Significant reduction of
OM grade in study group

35mW;
1.1J/cm2, 32
sec
30mW, 2 J/cm2,
time-NS

IO

CT/RT of H&N

Adult

Kelner
2007[24]

N - IV

IO

CT/RT of H&N

Adult

Zanin 2010[25]

Y - IV

830

60mW;
12J/cm2, timeNS

IO

CT/RT of H&N

Adult

Lima 2010[26]

Y - IV

808 /
660

40mW; 6J/cm2,
6 sec

IO

CT/RT of H&N

Mixed

Simoes
2009[27]

N - IV

IV

IV

No guideline
possible

No guideline
possible

LLLT and Chlorhexidine
have similar effects
Improves quality of life and
decreases incidence of
OM in patients with H & N
cancer treated with CT
and RT
Delayed appearance of
OM. Similar results for
LLLT and Aluminun
Hydroxide
Laser applied 3/week
maintains oral mucositis to
grades 1 and 2. Not
enough information to
allow for a conclusion

P

T

685

35mW; 2J/point
70J/cm2, 54 sec

IO

CT

Mixed

Abramoff
2008[28]

Y - IV

NS

NS

100mW for
“laser”; 50,
250,500mW for
“infra-red”, 2
J/cm2, 33 sec

IO

CT

Adult

GenotKlastersky
2008[20]

Y - III

NS

830

IO

CT

Adult

Wong 2002[29]

Y - IV

GaAlAs

685

45-50mW; 0.70.8J/cm2, 10-30
min c
35mW; 2J/point
70J/cm2, 54 sec

IO

CT

Mixed

Abramoff
2008[28]

Y - IV

InGaAlP

660 /
830

100mW;
2J/cm2, timeNS

EO

CT

Pediatric

Moraes
2009[30]

Y – IV

830

250mW; , 35
J/cm2, e

IE

CT

Adult

Nes 2007

Y-IV

GaAlAs

AsGaAl

Laser
diode

Laser
diode

T

LED

645±15

7.8mW;
0.99J/cm2, 5
min c

IO

CT

Adult

Corti 2006[31]

Y–V

T

NS

660

30mW; 2J/cm2,
66 sec

IO

Mixed: RT of
H&N & CT

Mixed

Sandoval
2003[32]

Y - IV

IV

No guideline
possible

IV

No guideline
possible

LLLT has both a
preventive and a
therapeutic role in those
prone to develop OM
Preventive laser therapy in
beneficial in reducing the
occurrence and intensity
of OM in patients with
solid tumors who have had
previous mucositis
Reduced incidence and
severity of OM
pain relief and possible
decrease in the severity of
OM
Both 830 and 660nm
lasers improved healing of
oral mucositis with extraoral application in pediatric
patients with established
oral mucositis
Study aimed at the
analgesic effect only

V

No guideline
possible

The median healing time
was 1.7 and in 7 L+
patients, was shorter than
in the L- group. The
healing rate increased
beneficial effects on the
management of oral
mucositis, improving the
quality of life

NS – not specified, P – prevention, T – treatment, IO – intra-oral, EO – extra-oral, HSCT – hematopoietic stem cell transplantation, w – with, wo – without, TBI – total body
irradiation, CT – chemotherapy, H&N – head and neck, RT – radiotherapy, Y – yes, N – no
– the Methods refer to the formula to calculate the time for each application point (t[s]=energy [J/cm2] X surface area [cm2]/Power [W]); the surface area was measured per
patient at baseline (numeric data are not reported in the source paper).
a

– the Methods specify “The treatment time for each application point was given by the equation t(s)=energy (J/cm2) X surface area (cm2)/Power (W); however, the surface area
was not reported neither stated it was measured.
c – time was specified per patient session and not per point of application.
d – it is not specified whether conditioning regimen included TBI or not.
e – time was not specified
Pediatric - <17 years old
b

Because of the variety of laser devices and the variation in individual protocols of
laser and other light applications in oral mucositis, it is important to keep in mind that the
results of each individual study apply exclusively to the cancer population studied, the
wavelength of the laser device, and the settings utilized in that particular study. One
additional issue that might play a role in the appearance and duration of oral mucositis is
the absolute neutropenia observed in cancer populations treated with myelosuppressive
therapies. 46 This confounder has not been evaluated in the majority of the trials and
should be included in future investigations of the applicability of LLLT in oral mucositis
prevention, treatment, and associated pain.
The mechanisms by which lasers promote beneficial effects in oral mucositis are
still speculative and extrapolated from other experimental models. For instance, lasers are
forms of coherent light emission. New technologies like LEDs and other non-coherent
light waves can also be absorbed by tissue chromophores and promote biological effects.
From the data available in the literature (Table 1) it seems that all effective light-therapy
devices work in similar wavelength bands concentrating around picks in 650 nm, 780 nm
and 830 nm. The 650 and 780 nm fall within the “red” range and the 830 nm fall within
the “near infra-red” (NIR) range. It is uncertain to what extent the difference in the
wavelength of the laser devices (for example 650 vs 632.8 nm) is meaningful in terms of
light-tissue interaction, however, in terms of clinical outcomes there were differences in
the effectiveness of certain wavelength and settings. It should be noted, there are no
studies assessing the effectiveness of laser or other type of light source in non-red or NIR
range. Thus, it may be possible that additional wavelength will be effective.
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With the advancement of the technology, the early high pricing laser emitting
devices has been reduced considerably, making the technology readily available.
Education and training of staff is another factor that must be considered when using
LLLT. Most of the protocols studied require daily and long applications. However, based
on the evidence available we predict that LLLT will be soon incorporated as a routine
practice in the prevention and treatment of oral mucositis and its associated pain. New
studies should focus on the determination of the most effective source of light, the setting
of theenergy to be delivered to the tissues, and the role of other confounders like cancer
type, cancer therapy, and extent of myelosuppression. The newly available blue LED
bring a new potential to the management of oral mucositis and research is warranted
based on the known effects of this light therapy in wound healing. 47
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